Fundz

Who to call at ReCode Therapeutics, and when

Fundz watches for the moments ReCode Therapeutics starts buying, and tells you who to reach.

  • An alert the day ReCode Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at ReCode Therapeutics, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

ReCode Therapeutics secures investment from Cystic Fibrosis Foundation to enhance research collaboration for a gene editing therapy targeting cystic fibrosis.

Aug 07, 2026
Menlo ParkBiotechnologyHealthcareHealth Care

Description

ReCode Therapeutics, a Menlo Park, Calif.-based clinical-stage genetic medicines company, received an investment from Cystic Fibrosis Foundation (CF Foundation). The amount of the deal was not disclosed. The company intends to use the funds to support its research collaboration with a gene editing partner for developing a novel gene editing therapy designed to correct mutations in the CFTR gene. Led by CEO Heather Clark, ReCode Therapeutics focuses on precision delivery of genetic medicines.

Company Information

Company

ReCode Therapeutics

Location

Menlo Park, California, United States

About

ReCode Therapeutics is a clinical-stage genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics. ReCode’s selective organ targeting (SORT) lipid nanoparticle (LNP) platform is a next-generation, genetic medicines technology that enables precise delivery to target organs and cells beyond the liver.

Related People

Priya
Senior decision-maker at this company
••••••••@••••••••

See Priya's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for ReCode Therapeutics's next move

Learn about Strategic plan

ReCode Therapeutics signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.